News Release | sareptatherapeutics.com: CAMBRIDGE, MA -- (Marketwired) -- 10/02/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced a new online resource center, called Let's Skip Ahead, for families affected by Duchenne muscular dystrophy (DMD) and their healthcare providers. The new website, available at www.skipahead.com, includes information and educational resources intended to make the science of exon skipping simple, and provides an opportunity to sign up for updates about upcoming Sarepta clinical trials.
http://www.skipahead.com/
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment